Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2613211 | Réanimation | 2010 | 4 Pages |
Abstract
Recombinant human activated protein C (APC) has been demonstrated to reduce the mortality rate of adult patients with severe sepsis. This effect was thought to be related to its anticoagulant and anti-inflammatory processes in severe sepsis. Indeed, data from the Prowess study demonstrated that the use of APC was associated with a quicker reduction in cardiovascular failure. Recent animal data have suggested that APC may improve both vascular and myocardial dysfunction and vascular reactivity to catecholamines during endotoxin and/or septic challenges. These effects appear to be related to an attenuation of endothelial cell-leukocyte activation and to a marked reduction in inflammation and oxidative stress at both the vascular and cardiac level.
Related Topics
Health Sciences
Medicine and Dentistry
Emergency Medicine
Authors
N. Sennoun, B. Levy,